Thursday, April 22, 2021
- Advertisement -
Home World Covid-19. European regulator gave 'green light': AstraZeneca vaccine is renamed Vaxzevria

Covid-19. European regulator gave ‘green light’: AstraZeneca vaccine is renamed Vaxzevria

The AstraZeneca vaccine against covid-19 changed its name to Vaxzevria after the approval of the European Medicines Agency (EMA), the regulator announced this Tuesday, disclosing that until last Thursday, 10 million doses of this vaccine had been administered. drug.

The information on the new designation of this vaccine – shrouded in controversy because the pharmaceutical company failed to agree with Brussels on deliveries to the European Union (EU) and the appearance of blood clots in vaccinees – is in an update to the product, this Tuesday published by the EMA.

In this Monday update on the drug, the EMA discloses that, in addition to the name change, “a warning about very rare specific blood clot events has been included in the product information, while further investigations are underway into a possible causal relationship with the vaccine “.

“Vaccinated people should seek immediate medical attention if symptoms of blood clotting and / or bleeding occur,” reinforces the regulator in the document, insisting that “the benefits of Vaxzevria in preventing covid-19 continue to outweigh the risks”.

In this update, the EMA further states that since the vaccine was approved in the EU on 29 January and until last Thursday, “more than 10 million doses of Vaxzevria have been administered in the EU and European Economic Area”, far below of the 120 million doses agreed between the pharmaceutical company and the European Commission for this first quarter.

- Advertisement -

Another controversy was related to the episodes of the appearance of blood clots and the death of people inoculated with this drug, which led most European countries, including Portugal, to suspend the administration of this vaccine for a few days, a situation that was overcome after the EMA guarantee. that it is “safe and effective”.

The product information issued by the EMA now contains the indication that “a combination of thrombosis and thrombocytopenia has been observed very rarely, in some cases accompanied by bleeding, after vaccination with Vaxzevria”, so health professionals “should be aware of Signs and symptoms”.

With regard to the European vaccination campaign, as of last Thursday, 18.2 million adults out of close to 400 million EU citizens had already received the second dose of the covid-19 vaccine, with the result that only 4, 1% of the European population was fully immunized.

Brussels attributed these low levels of inoculations to the problems in delivering vaccines from Vaxzevria to the EU, demanding that the pharmaceutical company catches up with delays in distribution and honors the contracted.

The Brussels target is that by the end of the summer, 70% of the adult population will be vaccinated. The data released by the institution last Thursday also revealed that 62 million doses of vaccines have already been administered in relation to the 88 million distributed.

Currently, four vaccines are approved in the EU: Pfizer / BioNTech (Comirnaty), Moderna, Vaxzevria and Janssen (Johnson & Johnson group, not yet in distribution).

By the end of this first quarter, according to Brussels, almost 100 million doses of vaccines will reach the EU, the vast majority from Pfizer / BioNTech (66 million, more than the 65 million initially agreed), from Vaxzevria (30 million). a total of 120 million initially agreed) and Moderna (10 million).

For the second quarter, the expectation of the community executive is that 360 million doses will reach the EU, mainly from Pfizer / BioNTech (200 million), from Vaxzevria (70 million from a total of 180 million initially agreed), from Janssen (55 million ) and Moderna (35 million).

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments